Abstract Library

#4626 Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Introduction: The efficacy and time to progression (TTP) following peptide receptor radionuclide therapy (PRRT) for pancreatic neuroendocrine tumours varies widely.

Conference:

Presenting Author: Papantoniou D

Authors: Tiensuu Janson E, Fröss-Baron K, Grönberg M, Ziolkowska B,

Keywords: prrt, pancreatic neuroendocrine tumour, predictive model,

#4196 Metastatic potential and associated mortality in a Greek cοhort of 123 MEN1 patients

Introduction: Prevalence of distant stage disease and overall mortality rates vary considerably among patients with multiple endocrine neoplasia type 1 (MEN1).

Conference:

Presenting Author: Papadopoulou-Marketou N

Authors: Papadopoulou-Marketou N, Daskalakis K, Chondrogianni M, Tsoli M, Kaltsas G,

Keywords: MEN1, pancreatic neuroendocrine tumor, thymus cancer,

#4114 Delays in the dosing administration of PRRT in advanced neuroendocrine tumors – Is there an adverse impact?

Introduction: Peptide receptor radionuclide therapy (PRRT) has emerged as a major therapeutic component in the overall management of advanced neuroendocrine tumors (NETs). In Greece, the treatment has been performed for several years, however because of reimbursement issues, especially during the financial crisis in Greece, there is usually a delay between the administered doses beyond the recommended 6-8 weeks interval.

Conference:

Presenting Author:

Authors: Georgakopoulos A, Tsoli M, Koumarianou A, Papadopoulou N, Panagaki M,

Keywords: PRRT, Progression-free survival, overall survival,

#4039 Long-term natural history of enterochromaffin-like cell (ECL) hyperplasia

Introduction: Enterochromaffin-like cell (ECL) hyperplasia in the context of autoimmune atrophic gastritis, over a period of time, can progress to gastric neuroendocrine tumors (g-NETs) type 1.

Conference:

Presenting Author:

Authors: Karapanagioti A, Panagaki M, Ioannidou K, Papadopoulou N, Kaltsas G,

Keywords: ECL hyperplasia, g-NET type 1, gastrin,

#3866 Treatment efficacy in 212 metastatic small intestinal neuroendocrine tumor grade 2 patients

Introduction: Small intestinal neuroendocrine tumors (Si-NET) are frequently studied as a single entity, irrespective of their grade, which is known to influence prognosis.

Conference:

Presenting Author: Papantoniou D

Authors: Papantoniou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K,

Keywords: small intestinal neuroendocrine tumor, grade 2, somatostatin analogues, PRRT, Ki-67, somatostatin-receptor negative,